KIDNEY CANCER: Should urologists be administering the new targeted therapies for kidney cancer?
"It depends on the circumstances of your practice," advised Robert G. Uzzo, MD, of the Fox Chase Cancer Center, Philadelphia, and moderator of the urothelial and renal cell carcinoma session. "At our cancer center, we co-manage the patients. I'm not afraid to start a patient on a drug, and I'm not afraid to see or operate on patients taking the drug."
"It depends on the circumstances of your practice," advised Robert G. Uzzo, MD, of the Fox Chase Cancer Center, Philadelphia, and moderator of the urothelial and renal cell carcinoma session. "At our cancer center, we co-manage the patients. I'm not afraid to start a patient on a drug, and I'm not afraid to see or operate on patients taking the drug."
In patients who have undergone nephrectomy, they will often return to their urologist if their cancer recurs.
"They are comfortable with you and you are comfortable with them. Should you treat those patients? I don't think there's a reason you can't, but you need to feel comfortable managing the side effects. You at least need a good trials nurse or a good oncology nurse who feels comfortable managing the patients' phone calls, because you will be getting phone calls from patients about their side effects from these drugs," Dr. Uzzo said.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
